Alumis Up On Phase 3 Envudeucitinib Success: Oral Psoriasis Therapy Shows Promise [Seeking Alpha]
Alumis Inc. (ALMS)
Company Research
Source: Seeking Alpha
Envudeucitinib demonstrated high efficacy for an oral agent, with two-thirds achieving PASI 90 and over 40% reaching complete clearance by Week 24. ALMS announced a $175 million public offering to fund regulatory and clinical advancement, with a 2026 NDA submission targeted. Valuation is high for a pre-revenue biotech, but ALMS is well capitalized with an 18-month cash runway and a promising market opportunity. AsiaVision/E+ via Getty Images Thesis Alumis Inc. ( ALMS ) saw some massive stock movement yesterday, closing at gains of 95%. This was, of course, due to some very promising results from their lead candidate, envudeucitinib. The company also saw the result announcement as a good This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not rec
Show less
Read more
Impact Snapshot
Event Time:
ALMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALMS alerts
High impacting Alumis Inc. news events
Weekly update
A roundup of the hottest topics
ALMS
News
- HC Wainwright & Co. Hikes Alumis Inc. (ALMS)'s Price Target To $40 From $20, Reiterates Buy Rating [Yahoo! Finance]Yahoo! Finance
- Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional SharesGlobeNewswire
- Alumis (NASDAQ:ALMS) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Alumis Announces Pricing of Upsized Public Offering of Common StockGlobeNewswire
- Alumis (NASDAQ:ALMS) had its price target raised by analysts at Guggenheim from $18.00 to $32.00. They now have a "buy" rating on the stock.MarketBeat
ALMS
Sec Filings
- 1/13/26 - Form 4
- 1/13/26 - Form SCHEDULE
- 1/12/26 - Form 4
- ALMS's page on the SEC website